Navigation Links
Targanta Submits Oritavancin New Drug Application
Date:2/11/2008

ommercializing innovative antibiotics to treat serious infections in the hospital and other institutional settings. The Company's pipeline includes oritavancin, a semi-synthetic lipoglycopeptide antibiotic currently awaiting U.S. regulatory approval, as well as a number of antibacterial agents in pre-clinical development. The Company has operations in Cambridge, MA, Indianapolis, IN, and Montreal, Quebec, Canada. To find out more about Targanta Therapeutics Corp. (Nasdaq: TARG), visit our website at http://www.targanta.com.

Safe Harbor Statement

This press release contains "forward-looking statements" that are made pursuant to the safe harbor provisions Section 21E of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risk and uncertainties, and actual future results may differ materially. Forward-looking statements may be significantly impacted by certain risks and uncertainties described in Targanta's filings with the Securities and Exchange Commission. The risks and uncertainties referred to above include, but are not limited to, risks related to Targanta's dependence on the success of oritavancin; delays in obtaining or a failure to obtain regulatory approval for Targanta's product candidates; failure of any approved product to achieve significant commercial acceptance in the medical community or receive reimbursement by third-party payors; unfavorable clinical trial results; failure to maintain and protect Targanta's intellectual property assets and to avoid infringing the intellectual property rights of others; competition from other pharmaceutical or biotechnology companies; Targanta's potential inability to init
'/>"/>

SOURCE Targanta Therapeutics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Targanta to Present at Lazard Capital Markets Fourth Annual Healthcare Conference
2. Targanta to Present at 9th Annual Mass Opportunities Investment Conference
3. Targanta Therapeutics Announces Pricing of its Initial Public Offering
4. Targanta Therapeutics to Have Significant Presence at 47th Annual ICAAC Meeting
5. MedImmune Submits Biologics License Application to FDA for Motavizumab
6. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
7. Exelixis Submits XL139 Diligence Report to Bristol-Myers Squibb
8. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
9. Cephalon Submits Supplemental New Drug Application for FENTORA
10. AMDL Submits Data to FDA for Clearance to Market Its DR-70(R) Diagnostic Test to Monitor Colorectal Cancer Patients
11. CV Therapeutics Submits Supplemental New Drug Application for Ranexa(R) (ranolazine extended-release tablets)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... and NEW YORK ... (NASDAQ: PTBI ), a biopharmaceutical company advancing ... announced today that its Korean marketing partner, Hanmi ... marketing approval in Korea from the country,s Ministry ... Korea Testing & Research Institute (KTR) for MuGard, ...
(Date:3/31/2015)... 31, 2015 Diasome Pharmaceuticals, Inc. ( ... Inc., that a United States patent has recently been ... , Entitled “Lipid Construct for Delivery of ... matter claims related to the use of Diasome’s proprietary ... injected insulin to more effectively reach the liver’s metabolic ...
(Date:3/30/2015)... Calif. , March 30, 2015  Multiple new ... positively affect several important health factors. From their impact ... to their positive effect on both gut health and ... 2015 (EB) detail our latest understanding of walnuts, inner ... Boston , this annual meeting attracts an ...
(Date:3/30/2015)... 2015 US-Australian drug discovery company, Novogen Ltd, ... Inc., and Yale University, on March 27 released pre-clinical ... presented as an oral presentation by Professor Gil ... the 62 nd Annual Scientific Meeting of the ... CA. In both in vitro ...
Breaking Biology Technology:PlasmaTech Biopharmaceuticals' Partner Hanmi Pharmaceuticals Receives Marketing Approval For MuGard In Korea 2PlasmaTech Biopharmaceuticals' Partner Hanmi Pharmaceuticals Receives Marketing Approval For MuGard In Korea 3Diasome Pharmaceuticals, Inc. Announces Notice of Allowance from US PTO for Liver Targeting System for Insulin 2New Findings Support the Benefits of Eating Walnuts on Overall Health 2New Findings Support the Benefits of Eating Walnuts on Overall Health 3New Findings Support the Benefits of Eating Walnuts on Overall Health 4Yale University and Novogen Release Data on Cantrixil Mode of Action 2Yale University and Novogen Release Data on Cantrixil Mode of Action 3Yale University and Novogen Release Data on Cantrixil Mode of Action 4
... Lynn Jordan , ... Introduction , ... commonly carried out using manual pipetting. As the demand for greater ... a necessity for most laboratories. The most critical aspect of an ...
... Jeff Cunningham and Lynn Jordan , ... USA , Introduction , ... an optional accessory to the Sciclone Advanced Liquid Handler (ALH). This device ... or columns of 96 and 384 well microplates for purposes of liquid ...
... Geoffrey Grove, Ed Alderman Applied Science and Technology, Caliper Life ... Monica Adams, Jason Brennan Development Integration, Amersham BioSciences, 800 ... Overview , ... to eliminate the requirement for extended bacterial growth prior to sequencing. ...
Cached Biology Technology:384 Well Pipetting Precision and Accuracy Testing Using the Sciclone Advanced Liquid Handler 2384 Well Pipetting Precision and Accuracy Testing Using the Sciclone Advanced Liquid Handler 3384 Well Pipetting Precision and Accuracy Testing Using the Sciclone Advanced Liquid Handler 4Precision Testing for the Sciclone Advanced Liquid Handler Z8 Option 2Precision Testing for the Sciclone Advanced Liquid Handler Z8 Option 3Precision Testing for the Sciclone Advanced Liquid Handler Z8 Option 4Precision Testing for the Sciclone Advanced Liquid Handler Z8 Option 5Scalable Automation of the TempliPhi DNA Sequencing Template Amplification and DYEnamic ET Terminator Sequencing Kits on the Sciclone ALH 3000 2Scalable Automation of the TempliPhi DNA Sequencing Template Amplification and DYEnamic ET Terminator Sequencing Kits on the Sciclone ALH 3000 3Scalable Automation of the TempliPhi DNA Sequencing Template Amplification and DYEnamic ET Terminator Sequencing Kits on the Sciclone ALH 3000 4Scalable Automation of the TempliPhi DNA Sequencing Template Amplification and DYEnamic ET Terminator Sequencing Kits on the Sciclone ALH 3000 5Scalable Automation of the TempliPhi DNA Sequencing Template Amplification and DYEnamic ET Terminator Sequencing Kits on the Sciclone ALH 3000 6
(Date:3/16/2015)... 2015 Between 16 and ... groundbreaking innovations in biometric identification at the CeBIT ...      (Photo: http://photos.prnewswire.com/prnh/20150316/735333 ) ... well at the forefront: the company,s all new ... Germany . BiometricGate is the ...
(Date:3/12/2015)... , March 12, 2015 ... a standardized identity and access management (IAM) solution ... implementation schedule. With Beta System,s new IAM package, ... best practices gleaned from multiple IAM implementations across ... the software as well as any necessary services ...
(Date:3/11/2015)... March 11, 2015   The Sync Project™ ... to scientifically measure and harness music to improve ... biometrics and objective measurements of physiology, enabling the ... scale in large populations. It is designed for ... clinicians perform rigorous studies and accelerate the discovery ...
Breaking Biology News(10 mins):DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3Beta Systems Fast Forward IAM Available Now: a Standardized IAM Package at a Fixed Price 2Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 2Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 3
... The technology - which makes plants significantly more ... use by US agricultural company Becker Underwood in collaboration ... spraying crops with jasmonic acid - a chemical naturally ... reduces pest attack. But crops treated with the chemical ...
... A chemotherapy drug that is supposed to help save ... fatal allergic reactions. A new study from ... pharmacovigilance program at Northwestern University Feinberg School of Medicine ... the FDA,s Adverse Event Report System between 1997 and ...
... Humans, from ancient exchanges of food to modern day home mortgages, ... on their own. It,s the basis of the economy, and it ... receive a payoff in return for taking a risk. When ... of the housing market, the economy slows. The willingness to ...
Cached Biology News:Natural seed treatment could drastically cut pesticide use 2Common chemotherapy drug triggers fatal allergic reactions 2Common chemotherapy drug triggers fatal allergic reactions 3Researchers shed light on trading behavior in animals -- and humans 2
Chicken polyclonal to ADI1 ( Abpromise for all tested applications). Antigen: Full length native protein (purified), corresponding to amino acids 1-179 of Human ADI1. Entrez GeneID: 55256 ...
Rabbit polyclonal to EDG2 ( Abpromise for all tested applications). entrezGeneID: 1902 SwissProtID: Q92633...
... Synthetic peptide derived from the internal region ... Specific for the internal region of ... identifies the target band at ~590 kDa. ... secreted media from primary tracheobranchial epithelial cultures ...
...
Biology Products: